

GAMBIA - Pneumococcal Vaccine Support

This Decision Letter sets out the Programme Terms of a Programme.

1. Country: Gambia						
2. Grant number: 1821-GMB-12d-X / 08-GMB-08c-Y / 09-GMB-08d-Y						
3. Date of Decision Letter: 22 December 2017						
4. Date of the Partnership Framework Agreement: 3 February 2014						
5. Programme title: New Vaccine Support (NVS), Pneumococcal Routine						
6. Vaccine type: Pneumococcal						
7. Requested product presentation and formulation of vaccine: Pneumococcal (PCV13), 4 dose(s) per vial , LIQUID						
8. Programme duration¹: 2009 - 2021						
9. Programme Budget (indicative): (subject to the terms of the Partnership Framework Agreement, if applicable)						
	2009-2017	2018	2019	2020	2021	Total ²
Programme Budget (US\$)	9,027,624 ³	667,500	904,500	959,500	964,000	12,523,124
10. Vaccine introduction grant (in US\$) / Product switch grant: Vaccine Introduction Grant of US\$ 506,250 disbursed in 2009.						
11. Indicative Annual Amounts: (subject to the terms of the Partnership Framework Agreement, if applicable) ⁴						
Type of supplies to be purchased with Gavi funds in each year		2009-2017	2018			
Number of Pneumococcal vaccines doses			198,600			
Annual Amounts (US\$)		US\$9,027,624 ⁵	US\$667,500			
12. Procurement agency: UNICEF. The Country shall release its co-financing payments each year to UNICEF.						
13. Self-procurement: Not applicable.						

¹ This is the entire duration of the Programme.

² This is the total amount endorsed by Gavi for the entire duration of the Programme.

³ This is the consolidated amount for all previous years. Annual amounts prior to 2017 include the costs of injection safety devices. Annual amounts for 2017 onwards include only vaccine costs and freight.

⁴ This is the amount that Gavi has approved.

⁵ This is the consolidated amount for all previously approved years. Annual amounts prior to 2017 include the costs of injection safety devices. Annual amounts for 2017 onwards include only vaccine costs and freight.

<p>14. Co-financing obligations: Reference code: 1821-GMB-12d-X-C</p> <p>According to the co-financing policy, the Country falls within the group Initial self-financing.</p> <p>The following table summarises the co-financing payment(s) and quantity of supply that will be procured with such funds in the relevant year.</p>										
Type of supplies to be purchased with Country funds in each year	2018	2019	2020	2021						
Number of vaccine doses	14,000	18,200	18,600	18,600						
Value of vaccine doses (US\$)	US\$42,265									
Total co-financing payments (US\$) (including freight)	US\$43,000	US\$55,500	US\$57,000	US\$57,000						
<p>15. Operational support for campaigns: Not applicable</p>										
<p>16. Additional reporting requirements:</p> <table border="1"> <tr> <td>Reports and other information</td> <td>Due dates</td> </tr> <tr> <td>To prepare for the annual procurement of vaccines, Country shall submit the following information in May each year: number of children to be vaccinated, vaccine stock levels including buffer stock, wastage rates, any proposed changes in presentation or minimum co-financing levels and vaccines received.</td> <td>May 2018</td> </tr> <tr> <td>In accordance with applicable Gavi processes, Country shall report on programmatic and financial performance.</td> <td>To be agreed with Secretariat</td> </tr> </table>					Reports and other information	Due dates	To prepare for the annual procurement of vaccines, Country shall submit the following information in May each year: number of children to be vaccinated, vaccine stock levels including buffer stock, wastage rates, any proposed changes in presentation or minimum co-financing levels and vaccines received.	May 2018	In accordance with applicable Gavi processes, Country shall report on programmatic and financial performance.	To be agreed with Secretariat
Reports and other information	Due dates									
To prepare for the annual procurement of vaccines, Country shall submit the following information in May each year: number of children to be vaccinated, vaccine stock levels including buffer stock, wastage rates, any proposed changes in presentation or minimum co-financing levels and vaccines received.	May 2018									
In accordance with applicable Gavi processes, Country shall report on programmatic and financial performance.	To be agreed with Secretariat									
<p>17. Financial clarifications: Country shall provide the following clarifications to Gavi*: Not applicable</p> <p><i>*Failure to provide the financial clarifications requested may result in Gavi withholding further disbursements</i></p>										
<p>18. Other conditions: Not applicable</p>										

On behalf of Gavi



Hind Khatib-Othman
Managing Director, Country Programmes

22 December 2017